Adoptive immunotherapy and high-risk myeloma
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma.
CommentsThe original article is available at https://www.mdpi.com/
Published CitationDuane C, O'Dwyer M, Glavey S. Adoptive immunotherapy and high-risk myeloma. Cancers (Basel). 2023;15(9):2633.
Publication Date6 May 2023
- Beaumont Hospital
- Published Version (Version of Record)